北京若生智能科技有限公司
Drug Database
CE

cefazolin dibenzylamine (Daren)

✓ Approved

Pfizer, Inc. · 小分子 · 小分子

什么是 cefazolin dibenzylamine？

cefazolin dibenzylamine 是一种小分子，由Pfizer, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Daren
公司Pfizer, Inc.
药物类别小分子
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, Pfizer, Inc.

治疗适应症

cefazolin dibenzylamine 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsUrinary tract infection✓ Approved
Infections and infestationsRespiratory tract infection✓ Approved

相关研究文献

PubMedGels (Basel, Switzerland)2026-10-26

Dual-Drug Chitosan Hydrogel Loaded with Metformin and Cefazolin for Antibacterial, Anti-Inflammatory and Antioxidant Treatment of Drug-Resistant Bacteria-Infected Skin Wounds.

Zhang Yilin Y, Cao Jie J, Yan Yong Y, Li Zhaoyang Z et al.

Bacterial-infected skin wounds, especially those caused by drug-resistant pathogens accompanied by persistent inflammation, remain a major clinical therapeutic challenge. Rising antimicrobial resistance compromises the therapeutic effect of conventional single-agent antibiotics, creating an urgent demand for novel wound therapeutics that integrate bactericidal potency, immunomodulation and tissue regeneration capacity. In this work, an injectable multifunctional chitosan-based hydrogel (C@MC) was developed, which simultaneously incorporates metformin hydrochloride (as a potential antibiotic adjuvant) and cefazolin sodium (as a β-lactam class antibacterial drug). The optimized C@MC possesses interconnected three-dimensional pores with an initial storage modulus of ~0.83 kPa (C@MC360), featuring desirable mechanical strength, injectability, tissue adhesion and dual pH/glucose-responsive sustained drug release. In vitro evaluations revealed the dose-dependent bactericidal activity of C@MC against Staphylococcus aureus (S. aureus), Escherichia coli (E. coli) and New Delhi metallo-β-lactamase-1-producing E. coli (NDM-1 E. coli, resistant bacteria). The highest drug-laden group nearly eliminated all wound bacteria in vitro. It scavenged reactive oxygen species (ROS) to lower cellular MDA levels and suppress pro-inflammatory TNF-α and IL-6 in LPS-stimulated RAW 264.7 macrophages. In full-thickness mouse wounds infected with NDM-1 E. coli, C@MC360 achieved nearly complete wound closure, with only a 4.2% residual wound area on day 14, accompanied by suppressed inflammatory infiltration and accelerated wound regeneration. This dual-drug hydrogel integrates antibiotic potentiation, anti-inflammation and antioxidation, providing an intervention regimen for skin wounds infected with drug-resistant bacteria.

PMID 42929911
阅读全文 →
PubMedAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2026-10-25

Pharmacy performance evaluation: A single-center assessment of drug waste and mitigation strategies.

Tartera Kelly K, Harris Rachel D RD, Hughes Kristen K, Moore Ben B et al.

This case study evaluates 2 years of sterile medication compounding at a pediatric oncology institution to identify opportunities for increased operational efficiencies that reduce medication waste. The primary outcome for this case study was the rate of fully returned sterile compounded doses relative to the total number of dispensed sterile compounded doses during the study period, calculated as the percentage of returned drugs. Secondary outcomes included categorization of the most frequently returned therapeutic classes and dispense codes. Major goals of this case study included the following: (1) quantify the proportion of doses returned relative to the total prepared through the intravenous workflow management system (IVWMS), (2) compare year-to-year differences in return rates, (3) characterize the therapeutic classes most frequently associated with returned doses, and (4) assess the impact of operational interventions on return trends over time. Medication returns were reviewed over time to evaluate the impact of operational interventions to reduce waste. Select interventions included updates to batch inclusions/times, changing the default start time from midnight to 8 AM, addition of cefazolin premix, restriction of intravenous fluid auto-dispensing, and updated extended stability parameters for cyclophosphamide and cyclosporine. Across the 2-year period, the overall medication return rate decreased from 9.68% to 7.31% despite an increase in total doses prepared. A reduction in returns was seen for continuous infusion, continuous infusion premix, and intravenous piggyback (IVPB) mixtures. Central pharmacy returns declined from 10.5% to 8%. Implementation of targeted operational changes led to a reduction in returned intravenous compounded medications, demonstrating the effectiveness of these efforts in reducing waste. Across the study period, anti-infective agents and continuous infusion mixtures consistently stood as top contributors to drug returns, which reflects our unique population of pediatric oncology patients.

PMID 42921715
阅读全文 →
PubMedCureus2026-10-25

Antimicrobial Resistance of Bacteria Isolated From Patients With Cancer.

Valente-Morales Yetzil Y, Quintana-Ponce Sandra S, Kuri-Guinto Margarita Y MY, Díaz-Gonzaléz Sacnite D SD et al.

Cancer patients are at high risk of developing infections caused by multidrug-resistant (MDR) microorganisms. Monitoring antimicrobial resistance (AMR) is essential for guiding treatment in this vulnerable population. This study aimed to evaluate AMR patterns and temporal evolution among clinical bacterial isolates-comparing pre-pandemic (2016-2019) versus pandemic (2020-2021) periods and care settings (outpatient vs. inpatient)-recovered from cancer patients at a tertiary care center in Guerrero, Mexico. An observational, cross-sectional, retrospective study was conducted between 2016 and 2021. A total of 1,019 strains were analyzed using WHONET 2023 software, following the Clinical and Laboratory Standards Institute (CLSI) M100 cut-off values. Categorical variables were compared using Pearson's chi-squared test (χ²). For antibiotics with absolute frequencies less than 5, Fisher's exact test was applied using STATA statistical software version 14.2 (StataCorp LLC, College Station, TX, USA). Enterobacteriaceae accounted for 73.1% of the isolates, with Escherichia coli (42.3%, n = 431) and Klebsiella pneumoniae (14.0%, n = 143) being the predominant strains. The overall prevalence of extended-spectrum beta-lactamases (ESBLs) was 22.6%. In E. coli, an increase in resistance was observed starting in 2019, with resistance rates > 80.0% for ampicillin and cefixime. When comparing the 2020 period with 2021, resistance in E. coli increased significantly for ciprofloxacin (χ² = 4.144, p = 0.042) and ceftriaxone (χ² = 4.100, p = 0.043). Regarding MDR, 51.0% of E. coli isolates were MDR, while 32.2% of K. pneumoniae strains exhibited extensive drug resistance (XDR). In addition, possible pandrug-resistant (PDR) phenotypes were identified in 14.3% of Acinetobacter spp. isolates. Isolates from hospitalized patients showed higher resistance rates compared to those from outpatients with regard to E. coli for ampicillin/sulbactam (χ² = 4.422, p = 0.035), piperacillin/tazobactam (χ² = 17.519, p < 0.001), and cefazolin (χ² = 6.746, p = 0.009). The results demonstrate a high predominance of Enterobacteriaceae among clinical bacterial isolates from the evaluated oncology population. E. coli exhibited the highest proportion of MDR phenotypes (51.0%), whereas K. pneumoniae showed the highest frequency of XDR (32.2%). The high level of resistance observed among isolates from hospitalized patients could help guide empirical treatment toward alternative therapeutic options.

PMID 42927103
阅读全文 →
PubMedChemistry, an Asian journal2026-10-23

Bifunctional Iridium Pincer Catalysis for (De)Hydrogenation of N-Heterocycles.

Selvarasu Selvakumar S, Jagirdar Balaji R BR

Base-free, reversible, acceptorless dehydrogenation of 1,2,3,4-tetrahydroisoquinoline (THIQ), 1,2,3,4-tetrahydroquinoline (THQ), and other N-heterocycles catalyzed by an Ir(III) pincer complex, [Ir(H)(Cl)(tBu4PNCNP)] (1), has been demonstrated. Quantitative yields were obtained in the cases of THIQ, THQ, and 1-Ph-THIQ. The catalyst (2.0 mol%) was found to be efficient for five cycles of the reversible process for THIQ. The dehydrogenation of THIQ and THQ proceeded with the rate constants of 1.54 × 10-1 and 0.79 ×10-1 h-1, respectively. The hydrogenation of isoquinoline (IQ) and quinoline (Q) gave rate constants of 1.31 × 10-1 and 0.53 × 10-1 h-1, respectively. IQ and Q coordinate to the metal center in complex 1 to form cis and trans isomers, [Ir(H)(Cl)(L)(tBu4PNCNP)] (L = IQ, cis- and trans-1-IQ; L = Q, cis- and trans-1-Q) at low temperatures. The reversible transformation was also investigated using trans-2,5-dimethylpiperazine. In the dehydrogenation of THIQ, no intermediate was observed experimentally prior to the complete dehydrogenation of THIQ to form IQ. Acyclic 2°-amines such as N-benzylaniline, dibenzylamine, N-methylbenzylamine, N-cyclohexylethylamine, diisobutylamine, and dibutylamine underwent transamination except N-isopropylaniline, in addition to the dehydrogenation reaction.

PMID 42909455
阅读全文 →
PubMedJournal of stomatology, oral and maxillofacial surgery2026-10-23

Safety and Efficacy of Adjunctive Prophylactic Nitroimidazoles in Low-Risk Intraoral Tumor Resection: A Randomized Controlled Trial.

Ju Jia J, Wang Yan Y, Yue Jiao J, He Zi-Kang ZK et al.

Surgical site infections (SSIs) in oral and maxillofacial surgery are predominantly polymicrobial, with anaerobes are involved in more than 70% of cases but are poorly detected by routine culture. Although guideline endorse nitroimidazoles as first-line prophylaxis, the considerable variation in resistance rates and safety profiles observed in practice has created a gap between evidence-based recommendations and clinical decision-making. To compare the safety and efficacy of metronidazole, tinidazole and ornidazole as adjunctive prophylactic agents for the prevention of SSI after low-risk intraoral tumor resection, and to provide evidence supporting the rational use of antibiotics. In this prospective, randomized, single-blind, single-center, exploratory trial, 160 adults undergoing low-risk intraoral tumor resection without flap reconstruction or implant placement were randomly assigned in a 1:1:1:1 ratio to receive ornidazole, metronidazole, tinidazole, or cephalosporin-only control treatment. All participants received perioperative cefazolin prophylaxis. The primary outcome was the cumulative incidence of SSI within 30 days postoperatively. Secondary outcomes included surgical incision healing, patient tolerance, and safety profile. Of the 160 randomized patients, 3 were excluded after randomization because they met an exclusion criterion, leaving 157 patients in the full analysis set (ornidazole, n=38; metronidazole, n=39; tinidazole, n=40; control, n=40), of whom 146 (93.0%) completed the 30-day follow-up. The cumulative incidence of SSI, defined as an infection documented on postoperative day 3 or newly documented between day 3 and day 30, did not differ significantly among the four groups (P = 0.781): 2.6% (1/38) in the ornidazole group, 5.1% (2/39) in the metronidazole group, 2.5% (1/40) in the tinidazole group, and 7.5% (3/40) in the control group. Compared with the control group, the absolute risk differences in 30-day SSI were -4.9% (95% CI, -17.4 to 7.1) for ornidazole, -2.4% (95% CI, -15.3 to 10.4) for metronidazole, and -5.0% (95% CI, -17.5 to 6.5) for tinidazole; the corresponding conditional odds ratios were 0.33 (95% CI, 0.01-4.43), 0.67 (95% CI, 0.05-6.21) and 0.32 (95% CI, 0.01-4.20), respectively. One deep incisional infection occurred in the tinidazole group and one in the control group; no organ/space infection occurred in any group. No statistically significant differences were observed in surgical incision healing or patient tolerance among the groups. Adverse events were recorded in 9 patients (5.7%) within the first 3 days and in 45 of the 146 patients (30.8%) who completed follow-up by day 30, these were predominantly local wound-related reactions, with no significant difference among the groups (P = 0.525 for the day-3 comparison and P = 0.078 for the day-30 comparison) and mild gastrointestinal discomfort was reported in 8 patients (5.1%). In this exploratory study, which was underpowered to detect small differences, adjunctive nitroimidazole prophylaxis did not significantly reduce the incidence of SSI. However, given the wide confidence intervals and limited statistical power, clinically meaningful benefit or harm cannot be excluded. These findings warrant confirmation in larger, adequately powered trials.

PMID 42913857
阅读全文 →
PubMedSurgical endoscopy2026-10-20

Are prophylactic antibiotics routinely necessary in laparoscopic adnexal surgery? A multicenter cohort study.

Miyata Hiromi H, Kobayashi Eiji E, Yasuda Miki M, Chien Hungwu H et al.

The benefit of routine prophylactic antibiotics for clean laparoscopic adnexal surgery remains unclear. We evaluated whether pre-incision cefazolin reduces the incidence of 30-day surgical site infections (SSIs), and we identified perioperative risk factors for SSIs. We conducted a multicenter retrospective cohort study using clinical data from Osaka University and six affiliated hospitals. Among 1,865 patients who underwent laparoscopic adnexal surgery for benign conditions, 1,678 were included after specified exclusions. Patients received either pre-incision cefazolin (n = 1,415) or no prophylaxis (n = 263) according to institutional policy. The primary outcome was the incidence of SSI during the 30-day postoperative interval, classified according to CDC criteria. The association between prophylaxis and SSI was evaluated using inverse probability of treatment weighting (IPTW). Propensity scores were estimated using age, body mass index, diabetes mellitus, endometriosis, and previous abdominal surgery. Risk factors for SSI were assessed using multivariable logistic regression analysis. Exploratory subgroup analyses were performed by repeating the same IPTW procedure within specified subgroups, and procedure-specific supplementary analyses were performed for ovarian cystectomy. SSI occurred in 1.1% of patients in both groups: 16/1,415 in the cefazolin group and 3/263 in the non-antibiotic group. In IPTW-adjusted analyses, the incidence of SSI did not differ between groups (1.1% vs. 1.2%; p = 0.915). In multivariable analysis, operative time ≥120 min was associated with SSI (adjusted odds ratio [aOR] 3.54, 95% confidence interval [CI] 1.41-8.85). In supplementary analyses restricted to an ovarian cystectomy subgroup, uterine manipulator use was associated with SSI (aOR 4.03, 95% CI 1.26-12.90). Routine prophylactic cefazolin was not associated with a significantly lower incidence of 30-day SSI after clean laparoscopic adnexal surgery. Given few SSI events and the potential for residual confounding, our findings support further evaluation of a selective rather than routine approach to prophylactic antibiotic use.

PMID 42897337
阅读全文 →

注册免费账户还可查看另外 6315 篇文献

免费注册查看全部文献 →

了解更多cefazolin dibenzylamine